bioRxiv Science⌕ Search

bioRxiv · 10.1101/528216

Identification of 12 cancer types through genome deep learning

Abstract

MotivationCancer is a major cause of death worldwide, and an early diagnosis is required for a favorable prognosis. Histological examination is the gold standard for cancer identification; however, there is a large amount of inter-observer variability in histological diagnosis. Numerous studies have shown that cancer genesis is accompanied by an accumulation of harmful mutations within patients genome, potentiating the identification of cancer based on genomic information. We have proposed a method, GDL (genome deep learning), to study the relationship between genomic variations and traits based on deep neural networks with multiple hidden layers and nonlinear transformations. ResultWe analyzed 6,083 samples from 12 cancer types obtained from the TCGA (The Cancer Genome Atlas) and 1,991 healthy samples from the 1000 Genomes project(Genomes Project, et al., 2010). We constructed 12 specific models to distinguish between certain types of cancers and healthy tissues, a specific model that can identify healthy vs diseased tissues, and a mixture model to distinguish between all 12 types of cancer based on GDL. We present the success obtained with GDL when applied to the challenging problem of cancer based on genomic variations and demonstrate state-of-the-art results (97%, 70.08% and 94.70%) for cancer identification. The mixture model achieved a comparable performance. With the development of new molecular and sequencing technologies, we can now collect circulating tumor DNA (ctDNA) from blood and monitor the cancer risk in real time, and using our model, we can also target cancerous tissue that may develop in the future. We developed a new and efficient method for the identification of cancer based on genomic information that offers a new direction for disease diagnosis while providing a new method to predict traits based on that information. Contactchenwenbin@genomics.cn

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sun, Y., Zhu, S., Ma, K., Liu, W., Yue, Y., Hu, G., Lu, H., Chen, W.. 2019-01-24. Identification of 12 cancer types through genome deep learning. https://doi.org/10.1101/528216

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Classifying tumors from broad category to hierarchical molecular subtype: an interpretable hierarchical framework for precision oncology

Precise tumor subtype classification is important for guiding personalized treatment, characterizing tumor heterogeneity, and investigating molecular mechanisms. However, most existing multi-label classification models use flat architectures and do not fully exploit the inherent hierarchical relationships and biological constraints among tumor types, which limits their performance and interpretability in complex, fine-grained pan-cancer classification. Here, we present the cancer Hallmark-based Hierarchical Recursive Model (HHRM) for pan-cancer hierarchical multi-label classification. HHRM integrates hierarchical label structures with recursive neural networks, enabling simultaneous modeling of multi-level dependencies from broad cancer categories to specific subtypes. We trained the model on a comprehensive pan-cancer cohort of 11,476 samples spanning 26 primary cancer types and 405 subtypes across up to eight hierarchical levels. HHRM achieved an accuracy of 0.7924 for predicting hierarchical tumor subtypes and was further evaluated on a validation dataset of 887 samples. Compared with other hierarchical modeling frameworks, HHRM achieved higher accuracy in all three output modes. Ablation experiments showed that replacing the hallmark-based graph convolutional network reduced model performance. On an independent dataset of 1,608 breast cancer samples, HHRM also achieved an accuracy greater than 0.86. Finally, we combined SHAP with a network-based method to rank and analyze predictive genes at different levels of the tumor hierarchy, which identified both known and potentially novel biomarkers for cancer diagnosis. In conclusion, to our knowledge, HHRM is the first hierarchical model for multi-level tumor subtype classification. Its competitive performance, combined with post hoc biological interpretation, suggests potential value for precision cancer diagnosis.

bioinformatics↗

A comparative transcriptomic framework across kidney organoid, assembloid, and transplantation models

Human kidney organoids recapitulate key aspects of renal development and have emerged as valuable platforms for disease modeling, nephrotoxicity screening, and therapeutic development. The field now includes a wide range of emerging protocols with distinct cellular compositions and maturation states, which complicates systematic comparison and model selection. Here, we integrated single-cell and single-nucleus transcriptomes from 11 studies spanning kidney organoid and assembloids, both in vitro and following transplantation, benchmarked against fetal and adult kidney references. Transcriptional maturation toward adult identity is compartment specific and does not correlate with protocol complexity. Assembloid protocols show the most adult-like podocyte and distal nephron signatures, transplantation is associated with enhanced tubular oxidative metabolic features, only protocols incorporating ureteric progenitors reliably generate collecting-duct lineages, and no protocol achieves mature adult proximal tubule identity. Annotating against either fetal or adult kidney reference alone leads to misassignment, because early fetal nephron epithelium transcriptionally resembles injury-dedifferentiated adult proximal tubule cells. Assembloid and transplantation models share elevated mechanosensing pathway expression independently of vascularization. Together, these findings provide a framework for kidney organoid model selection.

bioinformatics↗

OncoSpot enables benchmarking of cancer spatial transcriptomics methods across tumor evolutionary modes

Spatial transcriptomics (ST) is increasingly used to map clonal architecture within tumors, yet methods for analyzing cancer ST data are difficult to evaluate because real tumors lack ground truth for copy-number alterations (CNAs), subclonal identity, and malignant cell fraction. Existing ST simulators model normal tissue and do not represent tumor evolution, CNA-driven expression, or the spatial organization of malignant subclones. We present OncoSpot, a cancer-aware simulator of Visium-like spot-based ST data. OncoSpot combines a spatial evolutionary scaffold from DEMON, CNAs generated along the resulting clonal phylogeny with CNAsim, cancer-type-specific malignant transcriptional programs, and spatially clustered nonmalignant cell types, and aggregates cells into spots with known malignant fraction, subclone, and copy-number profiles. We demonstrate OncoSpot on high-grade serous ovarian carcinoma, colorectal cancer, and hepatocellular carcinoma, which represent three distinct modes of tumor evolution. Simulated subclones were spatially clustered and showed stronger phylogeny-space concordance than those generated by scCube under matched subclone populations. Benchmarking CopyKAT, CancerFinder, Clonalscope, and RCTD revealed cancer-dependent performance: Clonalscope recovered copy-number signals more accurately in ovarian and colorectal cancer, whereas CopyKAT performed better in hepatocellular carcinoma, reflecting both the assumptions of each method and the copy-number landscapes of the three cancers. OncoSpot's ground truth also exposed a failure mode in Clonalscope's malignant spot identification, in which tumor and normal labels were inverted, and allowed us to trace its cause. These method-dependent behaviors would be difficult to detect in real data. OncoSpot provides a framework for benchmarking CNA inference, subclone detection, malignant spot identification, and normal spot deconvolution, and its modular design and guidelines allow extension to additional cancer types. OncoSpot is freely available at https://github.com/compbio-mallory/OncoSpot.

bioinformatics↗